Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23216186 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL23215983 | 0.89 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL23230963 | 0.78 | PDE4B (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL23216868 | 0.77 | SLC6A4 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL29745423 | 0.76 | HTR2C (0.41) | SLC6A2SLC6A4SLC6A3KCNH2HTR2A | |
| SCHEMBL23215968 | 0.76 | HTR2C (0.41) | SLC6A2SLC6A4SLC6A3KCNH2HTR2A | |
| SCHEMBL23216739 | 0.74 | EED (0.48) | — | |
| SCHEMBL23216345 | 0.72 | HTR2C (0.50) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL29768364 | 0.72 | HTR2C (0.50) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL11361173 | 0.69 | HTR2C (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4041229-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114727991-A | Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | SLC6A2 1553/4885SLC6A4 1866/4885SLC6A3 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.